Introduction Cholestatic liver disease (CLD) is a progressive condition characterised by impaired bile formation and flow, leading to bile accumulation, liver injury, and eventual cirrhosis or liver failure. Despite advances in hepatology, treatment options remain limited, with ursodeoxycholic acid and obeticholic acid offering only partial benefit.
Introduction
Cholestatic liver disease (CLD) is a progressive condition characterised by impaired bile formation and flow, leading to bile accumulation, liver injury, and eventual cirrhosis or liver failure. Despite advances in hepatology, treatment options remain limited, with ursodeoxycholic acid and obeticholic acid offering only partial benefit. Increasing attention has been directed toward the gut–liver axis, particularly the role of gut microbiota and their metabolites in modulating liver disease.
Problem Statement
The key mechanisms driving CLD progression remain incompletely understood, and current therapies fail to adequately halt disease progression in many patients. Although berberine has shown hepatoprotective effects, its very low systemic bioavailability raises uncertainty about how it exerts clinical benefit, suggesting an indirect mechanism possibly mediated through gut microbiota.
Summary
This study demonstrates that orally administered berberine is converted by gut microbiota into dihydroberberine, which acts as the active metabolite. Dihydroberberine suppresses serotonin (5-HT) production in intestinal enterochromaffin cells by inhibiting tryptophan hydroxylase 1, thereby disrupting the 5-HT signalling axis involved in cholestatic injury. This mechanism was consistently validated across multiple animal models and further supported by clinical data showing improved biochemical markers and reduced 5-HT levels in patients. These findings highlight a novel microbiota-driven therapeutic pathway, positioning berberine as a promising candidate in CLD management.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.